Listen to the teleconference recording here:
Achromatopsia is a challenging inherited retinal disease causing extreme light sensitivity, as well as impaired visual acuity and color perception. Approximately 75 percent of cases are caused by mutations in the genes CNGA3 or CNGB3.
Applied Genetic Technologies Corporation (AGTC), Achroma Corp, and the Foundation Fighting Blindness hosted a one-hour teleconference on the condition. The call highlighted the difficulties patients have in getting a diagnosis for achromatopsia, the importance of genetic testing, and gene therapy clinical trials underway. Presenters included Dr. Christine Kay, a clinical trial investigator with Vitreo Retinal Associates (Gainesville, Florida), and Bridget Vissari, president of Achroma Corp, which is expediting cures for achromatopsia.
Current achromatopsia gene therapy clinical trials (all in phase 1/2) include:
MeiraGTx’s CNGA3 study (U.K.)
STZ eyetrial’s CNGA3 study (Germany)
Stay tuned to Eye on the Cure for updates on achromatopsia research.